Seres Therapeutics is a biopharmaceutical company developing live biotherapeutic products—orally administered consortia of engineered bacteria—to prevent infections and treat inflammatory immune diseases in medically vulnerable populations. The company's lead candidate, SER-155, is designed to prevent bloodstream infections in transplant and cancer patients by decolonizing pathogens and strengthening gut barrier integrity, with additional programs targeting inflammatory bowel disease, cancer immunotherapy-related side effects, and liver disease-related infections. Revenue to date comes from the sale of its FDA-approved microbiome therapeutic VOWST, and the company plans to generate future revenue through regulatory approval and commercialization of its pipeline candidates, while leveraging proprietary bacterial strain libraries, artificial intelligence-enabled platform technology, and manufacturing capabilities to design and produce therapeutic microbiome products.